Targeting Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Based on Risk of Intracranial Hemorrhage or Poor Functional Outcome: An Analysis of the Third International Stroke Trial [Clinical Sciences]
Conclusions—
There is a clinically relevant net positive effect of r-tPA in patients with acute stroke at a high predicted risk of sICH or poor functional outcome.
Clinical Trial Registration—
URL: http://www.controlled-trials.com. Unique identifier: ISRCTN25765518.
Source: Stroke - Category: Neurology Authors: Whiteley, W. N., Thompson, D., Murray, G., Cohen, G., Lindley, R. I., Wardlaw, J., Sandercock, P., on behalf of the IST-3 Collaborative Group Tags: Acute Cerebral Infarction, Emergency treatment of Stroke, Thrombolysis Clinical Sciences Source Type: research
More News: Clinical Trials | Emergency Medicine | Hemorrhagic Stroke | Ischemic Stroke | Neurology | Stroke | Thrombosis